CAS No.: 1475332-90-4
Molecular Formula: C30H35F3N4O3 | Molecular Weight: 556.62
Molecular Formula: C24H21F2NO3 | Molecular Weight: 409.43
Dosage Form: Oral Tablet (10mg) | Manufacturer: NewAmsterdam Pharma (Licensed by Amgen & Menarini Group)
Dosage Form: Oral Tablet (10mg) | Manufacturer: Merck & Co., Inc.
Product Overview
Obicetrapib is a novel oral selective Cholesteryl Ester Transfer Protein (CETP) inhibitor, developed by NewAmsterdam Pharma, with potent lipid-lowering efficacy and promising safety profile, currently in late Phase Ⅲ clinical trials globally, focusing on the "LDL-C+" comprehensive lipid-lowering concept.
Product Overview
Ezetimibe is an oral lipid-lowering drug, belonging to a selective cholesterol absorption inhibitor, widely used in the treatment of hypercholesterolemia with proven efficacy and good safety profile, approved globally for clinical use.
Mechanism of Action
• Specifically inhibits CETP activity, blocking the transfer of cholesteryl esters between HDL and ApoB-containing lipoproteins (LDL, VLDL), thereby increasing LDL-ApoB clearance and reducing circulating LDL-C levels significantly.
China [CN] 
Click enlarge Image